ANVS
HEALTHCAREAnnovis Bio Inc
$2.40+0.13 (+5.73%)PRE
Live · NYSE · May 9, Close
AI Insight
What's Moving ANVS Today?
No stock-specific AI insight has been generated for ANVS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.48$5.50
$2.40
Fundamentals
Market Cap$83M
P/E Ratio—
EPS$-1.40
Dividend Yield—
Dividend / Share—
ROE-2.2%
Profit Margin—
Debt / Equity—
Trading
Volume725K
Avg Volume (10D)—
Shares Outstanding34.6M
ANVS News
20 articles- Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026Yahoo Finance·May 7, 2026
- Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature PortfolioYahoo Finance·Apr 28, 2026
- Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA SubmissionYahoo Finance·Apr 10, 2026
- Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying WarrantsYahoo Finance·Apr 9, 2026
- Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain InfectionsYahoo Finance·Apr 2, 2026
- Annovis Publishes Historical Review of Buntanetap in The ScientistYahoo Finance·Mar 31, 2026
- NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical TrialYahoo Finance·Mar 19, 2026
- Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease StudyYahoo Finance·Mar 19, 2026
- Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial ResultsYahoo Finance·Mar 16, 2026
- Annovis Announces Two Presentations at the AD/PD™ 2026 International ConferenceYahoo Finance·Mar 3, 2026
- Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s DiseaseYahoo Finance·Feb 12, 2026
- Automotive Night Vision System Market to Reach US$ 9,138.4 Million by 2032 Driven by AI-Enabled Predictive Safety and Mainstream Adoption Beyond Luxury Vehicles | Astute AnalyticaYahoo Finance·Feb 10, 2026
- Annovis Announces Open-Label Extension Study for Parkinson's Disease PatientsYahoo Finance·Dec 18, 2025
- Annovis to Host Corporate Update Webinar on January 28, 2026Yahoo Finance·Dec 16, 2025
- Annovis To Present at the 2025 Annual Meeting of the Parkinson Study GroupYahoo Finance·Dec 3, 2025
- Annovis Announces Two Presentations at the CTAD 2025 ConferenceYahoo Finance·Nov 24, 2025
- Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease StudyYahoo Finance·Nov 18, 2025
- Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's PatientsYahoo Finance·Nov 17, 2025
- Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 12, 2025
- Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s ProgramYahoo Finance·Nov 6, 2025
All 20 articles loaded
Price Data
Open$2.29
Previous Close$2.27
Day High$2.38
Day Low$2.19
52 Week High$5.50
52 Week Low$1.48
52-Week Range
$1.48$5.50
$2.40
Fundamentals
Market Cap$83M
P/E Ratio—
EPS$-1.40
Dividend Yield—
Dividend / Share—
ROE-2.2%
Profit Margin—
Debt / Equity—
Trading
Volume725K
Avg Volume (10D)—
Shares Outstanding34.6M
About Annovis Bio Inc
Annovis Bio, Inc., a clinical-stage drug platform company, develops drugs to treat neurodegeneration. The company is headquartered in Berwyn, Pennsylvania.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNYSE
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—